{"id":244574,"date":"2026-09-28T13:02:19","date_gmt":"2026-09-28T18:02:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/09\/researchers-find-how-prostate-tumors-reshape-the-immune-microenvironment"},"modified":"2026-09-28T13:02:19","modified_gmt":"2026-09-28T18:02:19","slug":"researchers-find-how-prostate-tumors-reshape-the-immune-microenvironment","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/09\/researchers-find-how-prostate-tumors-reshape-the-immune-microenvironment","title":{"rendered":"Researchers find how prostate tumors reshape the immune microenvironment"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/researchers-find-how-prostate-tumors-reshape-the-immune-microenvironment.jpg\"><\/a><\/p>\n<p>Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment. A combined targeted therapy approach improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.<\/p>\n<p>The study, published in <em>Cancer Discovery<\/em>, was led by Di Zhao, Ph.D., associate professor of Experimental Radiation Oncology, and Nicholas Navin, Ph.D., chair of Systems Biology. The findings suggest that tumors use this pathway as a backup physical defense and may explain why therapies targeting the B7-H3 immune checkpoint may show limited <a href=\"https:\/\/www.news-medical.net\/health\/What-Does-Efficacy-Mean.aspx\">efficacy<\/a> when used alone.<\/p>\n<blockquote><p>Our study shows that the immune checkpoint B7-H3 does more than put the brakes on the immune system; it also reshapes the cells surrounding a tumor to help cancer grow and resist treatment. By uncovering how this process works, we identified a promising strategy that combines B7-H3-targeted therapy with MEK inhibition. These findings could help guide more effective, personalized treatments for patients whose tumors are unlikely to respond to B7-H3 therapy alone.<\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment. A combined targeted therapy approach improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer. The study, published in [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-244574","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/244574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=244574"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/244574\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=244574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=244574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=244574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}